SCHEMBL1796382

SCHEMBL1796382

ClCCOc1c(Br)cccc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.35
HTR7 P34969 1/20 0.34
LMNA P02545 4/20 0.34
MAPT P10636 3/20 0.34
MAPK1 P28482 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
HPGD P15428 1/20 0.34
KLK1 P06870 1/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
HRH3 Q9Y5N1 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C19 P33261 2/20 0.32
TSHR P16473 2/20 0.32
CYP2D6 P10635 1/20 0.32
NFKB1 P19838 1/20 0.32
HSD17B10 Q99714 1/20 0.32
IDO1 P14902 2/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1057982 0.81 SMN1; SMN2 (0.35) SMN1; SMN2HTR7LMNAMAPTMAPK1
SCHEMBL9957027 0.79 ALDH1A1 (0.46) SMN1; SMN2HTR7LMNAMAPTMAPK1
SCHEMBL21991382 0.79 SMN1; SMN2 (0.42) SMN1; SMN2HTR7LMNAMAPTMAPK1
SCHEMBL4483072 0.79 TAAR1 (0.46) SMN1; SMN2MAPK1HPGDKLK1RAB9A
SCHEMBL20482100 0.79 SMN1; SMN2 (0.39) SMN1; SMN2HTR7LMNAMAPTMAPK1
SCHEMBL4953222 0.77 KLK1 (0.43) SMN1; SMN2HTR7LMNAMAPTMAPK1
SCHEMBL12646924 0.77 THRA (0.50) SMN1; SMN2LMNAMAPTMAPK1L3MBTL1
SCHEMBL1929353 0.77 HTR7 (0.58) SMN1; SMN2HTR7LMNAMAPTMAPK1
SCHEMBL28912859 0.77 MRGPRX4 (0.47) SMN1; SMN2HTR7LMNAMAPTMAPK1
SCHEMBL21899044 0.76 KMT2A (0.50) SMN1; SMN2LMNAMAPTMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951799-B2 sugar transport enhancement agent; antidiabetic and hypoglycemic agent; obesity, diabetic nephropathy, retinopathy, macrovascular disease, glucose tolerance anomaly; cyclization of 4-(2-aminocyclohexylamino)-3-pyrroline-2-one by aldehyde followed by acylation AJINOMOTO CO., INC. (JP) 2011-05-31 US disclosed
US-20080108604-A1 NOVEL LACTAM COMPOUND AJINOMOTO CO., INC. (JP) 2008-05-08 US disclosed
EP-1878734-A1 NOVEL LACTAM COMPOUND Ajinomoto Co., Inc. (JP) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108604-A1 NOVEL LACTAM COMPOUND SLC2A4, SLC2A1, SLC2A9 SMN1; SMN2 1021/4885HTR7 4625/4885LMNA 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.